UNSPSC 51294210: Oxaflozane hydrochloride

This classification denotes an antidepressant agent with the molecular formula C14H18F3NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E10FW59D1I, chemically known as 4-isopropyl-2-(alpha,alpha,alpha-trifluoro-m-tolyl)morpholine hydrochloride but more generally known as oxaflozane hydrochloride, which bears US NIH Compound Identifier 167466. European Medicines Agency schedules Oxaflozane hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03560MIG.

Most nations, for tariff and trade purposes, schedule oxaflozane hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, OXAFLOZANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)N1CCOC(C1)C2CCCC(C2)C(F)(F)F.CL.

UNSPSC 51294210 Oxaflozane hydrochloride is a Commodity code that does not align with the recent state and local procurement activity posted under it. The three most recent opportunities solicited under this code involve naloxone and drug deactivation systems, a direct-to-manufacturer prescription program for therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing — none of which include oxaflozane hydrochloride or compounds closely related to it. The apparent mismatch suggests either tagging error in the source data or that this specific chemical is rarely procured by state and local bodies, making the code an unreliable indicator of actual market activity for this commodity.

The recent opportunities do reflect broader pharmaceutical and health product procurement across state health departments, county health systems, and multistate cooperative purchasing alliances. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023 — a date inconsistency in the source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission issued a Request for Information in April 2026 on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson. Activity spans Florida, Texas, Minnesota, and Oregon, with MMCAP representing a multistate cooperative vehicle. The code shows little relevant recent activity for oxaflozane hydrochloride specifically.